Mr. Neher, this is our first interview without masks since the beginning of the pandemic. Will this remain so? Richard Neher: If the number of cases increases, wearing face masks again in some settings makes sense. This not…
Jump in at the deep end December 2015 With her Master’s in Biochemistry still warm in her hand, market analyses, pricing strategies and product launches were already waiting for her. Gabriela Güntherodt, at that time a…
Application and selection procedure The prestigious Biozentrum PhD Fellowships are awarded on a competitive basis. Shortlisted candidates are invited to the Biozentrum for a week of interviews with group leaders and other…
The company NextImmune , founded at the Biozentrum of the University of Basel in 2021, focuses on the development of selective immunosuppressive therapy. This novel class of drugs specifically suppresses the immune system…
Alumni Name Position Held in Lab Current Position BUCHAKCHIISKYI Volodymyr PhD Lab Technician graduate student, University of Basel, Switzerland DECKOVIC Najla Internship DELANEY Colin Research Associate Research Associate,…
The Biozentrum startup Translation-X is pioneering a precision medicine approach to address the core symptoms of autism-spectrum disorders such as social interaction difficulties. The company recently reached an important…
It was only at the beginning of the year that the Biozentrum spin-off Aukera Therapeutics qualified for the BaseLaunch Accelerator program. Now the two young entrepreneurs Dr. Stefan Imseng and Dr. Dritan Liko can add…
The project entitled «Development of a lead compound for specific mTORC1 inhibition» is the first Innosuisse funded project at the Biozentrum. Replacing the former Swiss Commission for Technology and Innovation (CTI), the…
Technology Ventures The primary goal of the basic research investigations in molecular and biomedical biology at the Biozentrum is to investigate central questions about the smallest unit of life, the cell, as well as vital…
“The closure of this financing round and the successful recruitment of 545 patients in our first clinical study at the University Hospital Basel this year is a huge success”, states Marija Plodinec, CEO of ARTIDIS. “We are…
This website uses cookies to collect data from users and improve functionality. By continuing to browse the site you are agreeing to this. Receive more information by reading our privacy policy.
